Is Family Care overvalued or undervalued?

As of 17 October 2025, the valuation grade for Family Care has moved from expensive to fair, indicating a reassessment of its market position. The company is currently deemed fairly valued, supported by a PE ratio of 0.79, an EV to EBITDA ratio of 0.95, and an impressive ROE of 219.63%.
In comparison to its peers, Family Care's valuation metrics stand out; for instance, Max Healthcare is categorized as very expensive with a PE ratio of 97.05, while Apollo Hospitals is also fair with a PE of 72.25. Notably, Family Care's PEG ratio is exceptionally low at 0.00, suggesting significant growth potential relative to its price. Despite recent underperformance, with a year-to-date return of -35.14% compared to the Sensex's 7.44%, the company's valuation metrics imply it may be an attractive opportunity for investors looking for value in the healthcare sector.